#USA #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense to Present Vital Data on PrimeC at AD/PD™ 2026 Conference

Overview

NeuroSense Therapeutics Ltd., a biotechnology company engaged in late-stage clinical trials for neurological diseases, has announced significant findings that will be discussed at the upcoming AD/PD™ 2026 International Conference in Copenhagen. This conference will focus on Alzheimer's and Parkinson's diseases, as well as related neurological disorders. Dr. Christian Lunetta, the presenter, will highlight the advancements made with PrimeC, especially in the context of amyotrophic lateral sclerosis (ALS).

Presentation Highlights

Scheduled for March 19, 2026, Dr. Lunetta's presentation is titled "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial." This talk will delve into essential clinical findings from a recent Phase 2b trial - PARADIGM, where PrimeC was tested on ALS patients. The results elucidated disease mechanisms and treatment impacts, guiding the design of the larger Phase 3 PARAGON trial currently underway.

Dr. Lunetta articulates the complexity of ALS and the need for therapies that intertwine clinical rigor with biological comprehension. "As we transition toward the PARAGON study, the insights gained through the PARADIGM trial serve as a pivotal foundation for our therapeutic strategies. I am eager to engage with the scientific community at the AD/PD 2026 conference and discuss these promising results," he stated.

Significance of the Data

The insights provided by the PARADIGM trial are crucial not only for understanding ALS better but also for refining therapeutic approaches. With ALS affecting over 5,000 individuals annually in the U.S. and marking a staggering annual economic burden of $1 billion, the necessity for effective treatments has never been more prominent. The forthcoming PARAGON Phase 3 trial aims to rigorously assess PrimeC's efficacy in slowing down ALS progression.

Dr. Shiran Zimri, VP of Research and Development at NeuroSense, added, "This presentation follows closely after the results from PARADIGM are published in JAMA Neurology. Sharing this information at a prestigious event like AD/PD 2026 allows us to foster deep scientific dialogue and ensure a clearer understanding of our clinical and biomarker findings from PARADIGM as we push on to the global Phase 3 study."

About PrimeC

NeuroSense’s PrimeC stands out as a promising drug candidate. It's an innovative extended-release oral formulation combining two established FDA-approved drugs, ciprofloxacin and celecoxib. This combination is designed specifically to target various biological pathways that contribute to neurodegenerative processes, especially focusing on ALS and Alzheimer's disease.

Conclusion

As NeuroSense Therapeutics gears up for the AD/PD™ 2026 Conference, anticipation builds around PrimeC’s potential. The outcomes from both the PARADIGM and the forthcoming PARAGON trials could significantly contribute to the treatment landscape for ALS, representing a beacon of hope in the face of a challenging and complex disease. With commitment and collaboration, the journey towards effective ALS therapies continues, and the global scientific community eagerly awaits further revelations from the conference.

For more details on the progress of PrimeC and NeuroSense’s initiatives, follow updates through their website and social media platforms.